CN104244972A - Lps疫苗 - Google Patents

Lps疫苗 Download PDF

Info

Publication number
CN104244972A
CN104244972A CN201380015455.4A CN201380015455A CN104244972A CN 104244972 A CN104244972 A CN 104244972A CN 201380015455 A CN201380015455 A CN 201380015455A CN 104244972 A CN104244972 A CN 104244972A
Authority
CN
China
Prior art keywords
salmonella
vaccine composition
antigen
vaccine
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380015455.4A
Other languages
English (en)
Chinese (zh)
Inventor
坂元隆一
坂口正士
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of CN104244972A publication Critical patent/CN104244972A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380015455.4A 2012-03-22 2013-02-19 Lps疫苗 Pending CN104244972A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-065162 2012-03-22
JP2012065162 2012-03-22
PCT/JP2013/054038 WO2013140919A1 (ja) 2012-03-22 2013-02-19 Ｌｐｓワクチン

Publications (1)

Publication Number Publication Date
CN104244972A true CN104244972A (zh) 2014-12-24

Family

ID=49222384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380015455.4A Pending CN104244972A (zh) 2012-03-22 2013-02-19 Lps疫苗

Country Status (9)

Country Link
US (3) US9345756B2 (cg-RX-API-DMAC7.html)
EP (1) EP2829281B1 (cg-RX-API-DMAC7.html)
JP (1) JP6088489B2 (cg-RX-API-DMAC7.html)
CN (1) CN104244972A (cg-RX-API-DMAC7.html)
BR (1) BR112014021959B1 (cg-RX-API-DMAC7.html)
ES (1) ES2708430T3 (cg-RX-API-DMAC7.html)
MX (1) MX362955B (cg-RX-API-DMAC7.html)
RU (1) RU2637448C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013140919A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106177937A (zh) * 2016-07-25 2016-12-07 江苏省农业科学院 鸡减蛋综合征和禽脑脊髓炎二联灭活疫苗及其制备方法
CN109486741A (zh) * 2018-12-20 2019-03-19 天津瑞普生物技术股份有限公司 一种副鸡禽杆菌的灭活方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104244972A (zh) * 2012-03-22 2014-12-24 一般财团法人化学及血清疗法研究所 Lps疫苗
KR20160061989A (ko) * 2013-10-03 2016-06-01 닛토덴코 가부시키가이샤 코점막 백신 조성물
CN114746113B (zh) * 2019-11-29 2025-11-14 勃林格殷格翰动物保健有限公司 针对副鸡禽杆菌和禽脑脊髓炎病毒和禽痘病毒的三联疫苗
EP4171623A4 (en) * 2020-06-26 2024-08-14 Zivo Bioscience, Inc. Positive latency effects on coccidiosis prevention and treatment via animal feed
US20220053799A1 (en) * 2020-06-26 2022-02-24 Zivo Bioscience, Inc. Positive latency effects on coccidiosis prevention and treatment via animal feed
CN116033923A (zh) * 2020-08-12 2023-04-28 齐沃生物科学股份有限公司 Variovorax病菌作为球虫病替代治疗的用途
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
WO2025260072A1 (en) * 2024-06-14 2025-12-18 Zivo Bioscience, Inc. Gram-negative bacteria for use in the prevention and treatment of disease in poultry
WO2026043873A1 (en) * 2024-08-19 2026-02-26 Elanco Us Inc. Inactivated salmonella vaccine formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713073B1 (en) * 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
JP4456698B2 (ja) 1999-07-16 2010-04-28 生化学工業株式会社 エンドトキシンショック抑制剤
WO2004052394A1 (en) 2002-12-06 2004-06-24 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria
EP1747262B1 (en) * 2004-05-14 2012-09-26 National Research Council Of Canada Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
US20050260225A1 (en) * 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
RU2377015C1 (ru) * 2008-04-29 2009-12-27 Николай Васильевич Пименов Вакцина инактивированная против сальмонеллеза голубей и способ ее применения
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
CN104244972A (zh) * 2012-03-22 2014-12-24 一般财团法人化学及血清疗法研究所 Lps疫苗

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEGUCHI K.等: "Efficacy of a novel trivalent inactivated vaccine against the shedding of Salmonella in a chicken challenge moedl", 《AVIAN DISEASES》 *
PAUL A. REBERS: "The effect of formalin-killing of Pasteurella multocida on the antigenicity and extractability of its lipopolysaccharide", 《CARBOHYDRATE RESEARCH,》 *
RAM PARKASH TIWARI等: "Immunobiology of Lipopolysaccharide (LPS) and LPS-Derived Immunoconjugates Vaccinate Mice against Salmonella typhimurium", 《MICROBIOL. IMMUNOL》 *
RAM PARKASH TIWARI等: "Immunobiology of Lipopolysaccharide (LPS) and LPS-Derived Immunoconjugates Vaccinate Mice against Salmonella typhimurium", 《MICROBIOL. IMMUNOL》, vol. 42, no. 1, 31 January 1998 (1998-01-31), pages 1 - 5, XP055162292, DOI: doi:10.1111/j.1348-0421.1998.tb01962.x *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106177937A (zh) * 2016-07-25 2016-12-07 江苏省农业科学院 鸡减蛋综合征和禽脑脊髓炎二联灭活疫苗及其制备方法
CN109486741A (zh) * 2018-12-20 2019-03-19 天津瑞普生物技术股份有限公司 一种副鸡禽杆菌的灭活方法
CN109486741B (zh) * 2018-12-20 2021-10-29 天津瑞普生物技术股份有限公司 一种副鸡禽杆菌的灭活方法

Also Published As

Publication number Publication date
JP6088489B2 (ja) 2017-03-01
US20170281745A1 (en) 2017-10-05
JPWO2013140919A1 (ja) 2015-08-03
BR112014021959B1 (pt) 2022-12-06
US9345756B2 (en) 2016-05-24
US20150086590A1 (en) 2015-03-26
ES2708430T3 (es) 2019-04-09
EP2829281B1 (en) 2019-01-16
MX362955B (es) 2019-02-26
EP2829281A4 (en) 2015-11-11
BR112014021959A8 (pt) 2022-10-18
BR112014021959A2 (cg-RX-API-DMAC7.html) 2017-06-20
RU2637448C2 (ru) 2017-12-04
EP2829281A1 (en) 2015-01-28
MX2014011305A (es) 2014-10-17
US20160228526A1 (en) 2016-08-11
WO2013140919A1 (ja) 2013-09-26
RU2014138021A (ru) 2016-05-20
US10279025B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
US10279025B2 (en) LPS vaccine
Liu et al. Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model
Dehghani et al. Efficacy of formalin-killed, heat-killed and lipopolysaccharide vaccines against motile aeromonads infection in rainbow trout (Oncorhynchus mykiss).
Wang et al. Immunization with outer membrane vesicles of avian pathogenic Escherichia coli O78 induces protective immunity in chickens
Yaguchi et al. Vaccination of chickens with liposomal inactivated avian pathogenic Escherichia coli (APEC) vaccine by eye drop or coarse spray administration
Aoki et al. Stationary phase culture supernatant containing membrane vesicles induced immunity to rainbow trout Oncorhynchus mykiss fry syndrome
Abd El-Ghany et al. A trial to prevent Salmonella enteritidis infection in broiler chickens using autogenous bacterin compared with probiotic preparation
Iritani et al. Biological activities of crude polysaccharide extracted from two different immunotype strains of Hemophilus gallinarum in chickens
JP6196677B2 (ja) 交差防御性サルモネラワクチン
KR20120129777A (ko) 약독화, 면역강화 살모넬라 엔테리티디스의 변이균주를 포함하는 살모넬라증 예방용 생균 백신 조성물
US10258680B2 (en) Campylobacter vaccine
US8647640B2 (en) Vaccine compositions and methods of use to protect against infectious disease
Ahmad et al. Preparation and comparative evaluation of conjugate and whole-cell killed vaccine candidates against Salmonella enterica serovar Typhimurium
US20140023684A1 (en) Vaccine Against Pasteurellaceae
RU2683027C2 (ru) Поливалентная иммунизирующая и/или терапевтическая композиция для применения при бактериальных инфекциях или пищевом отравлении, в частности сальмонеллёзе, способ получения этой композиции, её применение и вакцина, содержащая эту композицию
Gratacap Characterisation of Vibrio anguillarum for the development of vaccine in cod (Gadus morhua).
Emery Virulence factors, pathogenesis, and protection against colibacillosis in poultry
Nagdive Standardization of Large Scale Production of A: 1 Phage Lysate and It s Evaluation of across Serogroup and Serotype Protective Immune Response
Abhilash IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A NOVEL INACTIVATED/KILLED PASTEURELLA MULTOCIDA A: 1 VACCINE AGAINST FOWL CHOLERA IN CHICKEN
Elazomi et al. Salmonella Enteritidis’ Vaccine Produces
Dibb-Fuller The contribution of sef14, sef17, sef21 and flagella to the pathogenesis of salmonella enteritidis in poultry
BR112015008775B1 (pt) Vacina compreendendo um sorotipo do sorogrupo c1 de salmonella enterica
Dadrast Egg transmitted immunity to Salmonella typhimurium phage type 49 in the chicken
HK1216149B (en) Campylobacter vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141224

RJ01 Rejection of invention patent application after publication